Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis : An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)

THAOS Investigators2026-01-092026-01-092025-03THAOS Investigators 2025, 'Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis : An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)', Journal of Cardiac Failure, vol. 31, no. 3, pp. 525-533. https://doi.org/10.1016/j.cardfail.2024.06.0031071-9164https://hdl.handle.net/10641/7079Publisher Copyright: © 2024 The Authors9448347enginfo:eu-repo/semantics/openAccessTransthyretin amyloid cardiomyopathyreal-worldsurvivaltafamidisCardiology and Cardiovascular MedicineSDG 3 - Good Health and Well-beingJournal ArticleResearch Support, Non-U.S. Gov'tYesyesSurvival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis : An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Supervivencia en una cohorte en condiciones reales de pacientes con miocardiopatía amiloide por transtiretina tratados con tafamidisUn análisis del Transthyretin Amyloidosis Outcomes Survey (THAOS)/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article10.1016/j.cardfail.2024.06.003https://www.scopus.com/pages/publications/85200436488https://www.scopus.com/pages/publications/85200436488#tab=citedBy